Navigation Links
AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011
Date:5/29/2008

AMSTERDAM, May 30 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that positive interim data from its pivotal clinical trial with AMT's lead product Glybera(R) (AMT-011) were presented by the Principal Investigator, professor Daniel Gaudet, at the American Society of Gene Therapy Annual Meeting in Boston on May 29th. These data confirm the outcome of a previous study conducted in The Netherlands, demonstrating safety and efficacy of Glybera(R) for lipoprotein-lipase deficiency, a disease also known as Hyperlipoproteinemia (HPL) type I. Currently, there is no effective treatment or cure for this seriously debilitating and potentially lethal disease.

Study data

Glybera(R) is a gene therapy product that corrects the genetic defect in lipoprotein-lipase (LPL) deficient patients. LPL is normally produced in muscle tissue and is needed to break down the large fat-carrying particles that circulate in the blood after each meal. As a result, LPL-deficient patients have very high fat (triglyceride) levels in their blood which may lead to recurrent episodes of pancreatitis, insulin resistance, and fat accumulations in skin as well as liver and retina.

In the pivotal study conducted in Quebec (Canada), patients with LPL-deficiency were first enrolled in an observation study and subsequently treated in a study in which there are two different dose groups. All patients showed very high fat levels in the observation study and had experienced (recurrent) pancreatitis episodes prior to treatment. To date 6 patients have been treated with the lower dose and 7 with the higher dose.

Professor Gaudet presented data on the first 10 patients, of which 6 were in the lower dose group and 4 were in the higher dose group. The data showed that treatment was well tolerated. Fat concentrations were reduced after treatment in all patients, with one exception. In all patients
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products to treat voiding dysfunctions, today reported financial results ... Global revenue for the Company,s Urgent ® ... new quarterly revenue record, as compared to $3.9 million ...
(Date:1/22/2015)... 22, 2015  Amgen (NASDAQ: AMGN ) today announced that ... results on Tuesday, Jan. 27, 2015, after the close of the ... call with the investment community at 2 p.m. PT. Participating in ... chairman and chief executive officer, and other members of Amgen,s senior ...
(Date:1/22/2015)... PARK, Calif. , Jan. 22, 2015 Increasing ... the continued consolidation of localization purchasing in 2015, says ... According to a recent study by market research ... chose a single-source solution for their translation and localization ...
Breaking Medicine Technology:Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... , WOODLAND HILLS, Calif., Oct. 28 Infor-Med Corporation, ... the beta release of Praxis Version 5 featuring Datum, ... to create, store, and share discrete clinical data. The ... funds and is designed to meet future ,meaningful use, ...
... Calif., Oct. 28 Cell Biosciences, Inc. today announced ... Corp. (OTC Bulletin Board: APNO). The stockholders of Alpha ... other conditions have been satisfied. Pursuant to the merger ... stockholders will receive $1.50 per share, or approximately $17.9 ...
Cached Medicine Technology:Praxis Electronic Medical Records Announces New Version 5 With Breakthrough in EHR Documentation 2
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, AZ has ... (PPHA). The PPHA's passion for others' well-being and shared ... treated for obstructive sleep apnea (OSA) has propelled them into ... the valley. The most recent plans for an event will ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the ... in an effort to further promote visibility and adoption of ... long made AMA journals available via its subscription services, EBSCO ... Network. , Long known as both a subscription ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... study at different dosages , , THURSDAY, April 23 (HealthDay ... grape seed extract lowers hormone levels in postmenopausal women ... the City of Hope cancer center in Duarte, Calif. ... inhibits aromatase, an enzyme that helps in estrogen production, ...
... other ,high-glycemic, carbs, researchers say , , THURSDAY, April 23 (HealthDay ... a workout may influence how many calories you burn during ... breakfast rich in carbohydrates that do not cause a spike ... -- burned 50 percent more fat during a post-breakfast workout ...
... LOUIS, April 23 Sigma-Aldrich Corporation, a leading Life Science ... diluted EPS grew by 6% to $0.68 from $0.64 in ... of 2009 were $519 million, a decline of 9% from ... first quarter sales grew organically by 1% from a year ...
... with grave concerns about the care of their patients at ... directly to Heather Howard, New Jersey Commissioner of Health and ... at about 11:30 a.m.Some 80 Registered and Practical nurses, members ... Health Care Employees, have been without a contract for a ...
... LAIYANG, China, April 23 /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, ... pharmaceutical company with its principal operations in the ... changed its name to "Jiangbo,Pharmaceuticals, Inc." ("Jiangbo"). , ... from the Department of State of the,State of ...
... a pioneer in assisting clients achieve next generation clinical and ... announced that CEO, Dr. Randall Williams, will partner with four ... Telemedicine Association,s 2009 conference in Las Vegas., ... April 27, 2009 @ 9:15 a.m. with Dr. Thomas ...
Cached Medicine News:Health News:No Verdict Yet on Grape Seed Extract vs. Breast Cancer 2Health News:A Pre-Workout Meal to Help You Burn Fat 2Health News:A Pre-Workout Meal to Help You Burn Fat 3Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 2Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 3Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 4Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 5Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 6Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 7Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 8Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 9Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 10Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 11Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 12Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 13Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 14Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 15Health News:Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name 2Health News:Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name 3Health News:Pharos Innovations and Clients to Showcase Three Client Case Studies at Upcoming ATA Conference 2
... PLIF instrument set consists of modular ... nerve root protectors, for bone graft ... bone blocks of the Lumbar I/F ... preparation which is important for graft ...
... consists of modular shavers and spreaders that ... space, and prepare the endplates for graft. ... for effective interbody fusion the disc and ... Gradual distraction of the disc space by ...
... The Access Dilation Port enables the ... a minimally invasive approach using step dilation. ... is gently pushed aside, creating space for ... port allows the surgeon to operate with ...
... screw insertion assembly incorporates slotted guides ... locking. The PathFinder MIS System uses ... pedicle screw insertion assembly incorporates crescent-shaped ... The evolutionary Pathfinder MIS pedicle screw ...
Medicine Products: